^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Excerpt:
To characterize the activity of ponatinib in estrogen receptor (ER)-positive breast cancer cells with dysregulated FGFR1, we studied MDA-MB-134 cells in which FGFR1 is amplified. Ponatinib potently inhibited MDA-MD-134 cell growth with a GI50 value of 23 nmol/L (Fig. 5A) and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L (Supplementary Fig. S4A).
DOI:
10.1158/1535-7163.MCT-11-0450
